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Abstract
Background: The main purpose of the study was to quantify the direct costs of oral cancer
treatment to the healthcare system of Greece. Another aim was to identify factors that affect costs
and potential cost reduction items. More specifically, we examined the relationship between stage
of disease, modality of treatment and total direct costs.
Methods: The medical records and clinic files of the Oral and Maxillofacial Clinic of the Athens
General Hospital "Genimatas" were abstracted to investigate clinical treatment characteristics,
including length of hospitalization, modes of treatment, stage of disease etc. Records of 95 patients
with oral squamous cell carcinoma (OSSC), with at least six months of follow-up, were examined.
The clinical data was then used to calculate actual direct costs, based on 2001 market values.
Results: The mean total direct costs for OSSC treatment estimated at euro 8,450 or
approximately US$ 7,450. Costs depended on the stage of the disease, with significant increases in
stages III and IV, as compared with stages I and II (p < 0.05). Multi-modality treatment applied mainly
to patients in stages III and IV was the factor that affected the cost. Disease stage was also
associated with the total duration of hospitalization (p < 0.05).
Conclusions: The clinical management of advanced oral cancer is strongly associated with higher
costs. Although the ideal would be to prevent cancer, the combination of high-risk screening, early
diagnosis and early treatment seems the most efficient way to reduce costs, and most importantly,
prolong life.
Introduction
Oral cancer (OC) has been recognized as a significant
health hazard with substantial management difficulties.
In Greece, the estimated annual incidence of OC is 600–
650 new cases [1]. Oral cancer is associated with signifi-
cant morbidity, and low survival. Its management often
causes adverse effects, such as disfigurement. Regarding
costs, the introduction of new diagnostic, pharmacologi-
cal and treatment technologies of the last decade, contrib-
ute towards such high costs, although the survival rate
remains unchanged [2]. Although it is a relatively rare dis-
ease, the fact that healthcare costs are rising fast (above in-
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with treating advanced cancer [3] do present a significant
challenge for the Greek economy. Ways and methods to
control such expenses are needed. As oral cancer affects
mainly persons above 60 years of age, future cost projec-
tions identify a significant and alarming increase, as a re-
sult of longer survival and the reduction of competing
mortality causes.
Methodological advances in the field of health economics
have allowed for an increased understanding of the role of
proper economic analyses in medical decision making [4–
7]. A common concern to all four main techniques of eco-
nomic studies, namely cost analysis, cost-benefit, cost-ef-
fectiveness and cost-utility, is the actual definition of cost.
The economic definition of cost of an intervention is cal-
culated as the value of the consumed resources, if those re-
sources had been put to use for an alternative service.
Using this definition, it becomes apparent that hospital
charges do not necessarily represent true hospital costs
[7]. Agreeing to the above, Luce et al. propose that it is the
use of the resource rather than the monetary exchange
that defines the direct cost, emphasizing that a valid anal-
ysis needs to capture "true costs" rather than "charges" [8].
The second consideration relates to the comprehensive ac-
counting of all resources consumed or gained as a result of
surgical intervention. Direct costs are represented by such
items as hospital room costs, laboratory costs, operating
room costs, and physicians' charges. A number of addi-
tional costs less easily defined, remain to be considered.
They are often referred to as indirect costs, and may in-
clude income loss from employment, loss of productivity
due to pain or disfigurement, rehabilitation costs (speech
therapy, implant placement, etc).
The last consideration relates to the perspective that the
analysis is viewed. Economic analysis can be performed
from a number of perspectives, including the perspective
of the patient, the health care provider, the insurance
company, the State or the society at large. Each of these
different entities will realize the economic effect of the
true costs differently. In this study, direct costs were calcu-
lated from the perspective of the health care system.
Healthcare professionals that treat OC patients in Greece
recognize the economic burden incurred to the family and
society; however, they may not be aware of the actual
monetary figures. The present study attempts to quantify
the OC treatment direct costs to the healthcare system.
The data was derived from hospital records of 95 OC pa-
tients treated at the Athens General Hospital "G. Genima-
tas" between 1993 and 1999. Apart from its descriptive
nature, this work attempts to identify potential cost reduc-
tion strategies and to examine the relationship between
stage of disease, treatment modality and monetary costs.
Materials and Methods
As a first step to this work, we performed a hospital record
review of the Oral and Maxillofacial Clinic of the Athens
General Hospital "G. Genimatas". A total of 95 records
were located and reviewed. Records belonged to patients
been diagnosed with squamous cell carcinoma of the oral
cavity (OSSC) between January 1st 1993 and December
31st 1999. Patients should have histologically confirmed
malignancies of the oral cavity, including the tongue,
floor of the mouth, buccal mucosa, gingival tissues, retro-
molar trigon, palate, and lips, but excluding tumors of the
oropharynx or pharynx. The ICD-10 coding for the above
lesions are as follows: C00.3-C00.9, C01-C06. An addi-
tional rule was that at least six months of close follow-up
should be recorded. The definition of close follow up was
intended to be uniform for all patients, according to the
clinic's policy, as follows: weekly for a month, and month-
ly for the remaining 5 months. After the first 6 months,
patients had to be followed every 3 months for half a year
and biannually thereafter. We chose a total follow up pe-
riod of 3 years, to accommodate the 1999 patients. The
clinical data was then used to calculate direct costs with
2001 price values, as explained later.
All records were checked against the clinic's database to
verify the diagnosis, inpatient hospitalization period and
length, clinical stage, operating room (O.R.) visits, the
need for radiation therapy, chemotherapy and finally the
need for reconstruction as well as complications, second-
ary operating procedures and intensive care unit (I.C.U)
days.
Billing records of the hospital were not used to derive
costs because hospital charges of the national healthcare
system (NHS) do not accurately reflect true healthcare
costs. As hospitals are subsidized by the State, charges are
grossly under-priced to accommodate NHS's policy to
provide universal hospital coverage.
Costs were calculated by multiplying in-patient hospitali-
zation and clinical procedures with a fair and customary
fee and by adding expense items such as operating room
charges, physician charges, radiation therapy and chemo-
therapy costs. Prices were sought in official publications
or professional association catalogues. For example, pric-
es for the chemotherapeutic medications were found in
Pharmacopoeia. Medication prices are set by the Ministry
of Trade and enforced by EOF, the National Organization
for Pharmaceuticals (the FDA or EMEA analogue in
Greece). Where no price was readily available or refer-
enced in professional association publications, we ob-Page 2 of 8
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three quotes obtained by 3 private hospitals. The exact
cost categories and price values are presented in Figure 1.
To illustrate the above, we present a calculation of the
costs for an actual case of OSSC. The patient was diag-
nosed with a T2N1M0 (stage III) oral squamous cell carci-
noma of the mandibular alveolar process. The treatment
involved surgical resection, as well as post-operative radi-
ation therapy. The patient developed a recurrence 11/2
years later, for which he was treated with a second surgical
operation. The final reconstruction included the place-
ment of a titanium reconstruction plate. The patient was
hospitalized for a total of 122 days. Based on the above,
we calculated the cost as follows:
Cost = Hospitalization costs + O.R costs + Surgeon's and
Anesthesiologist's Fees + Post-op RT + Reconstruction
plate 
Cost (in euros) = 19,692 + 980 + 2,318 + 968 + 646 =
24,604 (~ US$ 22,200)
Data management and statistical evaluation was per-
formed in two stages: first, descriptive statistics were calcu-
lated using MS Excel. Then, we used STATA 6.0 for
Windows (Stata Corp.) to perform analytic work, and
more specifically to identify what factors affect the fluctu-
ation or variability of cost among the 95 cases. Multivari-
ate linear regression was employed to identify predictors
of cost (expressed as the log transformation of cost), as
well as predictors of prolonged hospitalization.
Results
The TNM stage distribution of the patients and tumor lo-
cations are presented in Table 1. All patients had a biopsy
to confirm the diagnosis of malignancy. Approximately
half of the patients (44%) were classified as stage III, one
third (32%) was classified as stage II, 13% belonged to
stage IV and the remainder 10% were classified as stage I.
Among the 95 operations performed to remove the tu-
mor, 47 were considered of medium intensity and 48
were considered as major operations. Further, 17 subjects
received chemotherapy and 56 subjects received radiation
therapy.
Graph 1 lists the estimated costs per stage. It was observed
that costs depended on the stage of the disease, with sta-
tistically significant increases (p < 0.05) in stages III and
IV, as compared with stages I & II. More specifically, for
Figure 1
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their mean hospitalization period was 14.6 days, with a
range from 8 to 30. The most prevalent location was the
tongue and the floor of the mouth (6 cases), followed by
the lip (3 cases) and the bucal mucosa (1 case). Mean
treatment cost per patient was euro 3,815 (~ US$ 3,400).
The mean cost for Stage II (T2N0M0) patients was euro
6,112 (~ US$ 5,400) and their mean hospitalization was
30,3 days, with a range of 6 to 72. The primary location of
the tumor was mainly the floor of the mouth (11 cases)
and the lip (8 cases), followed by the tongue (7 cases), the
alveolar process (5 cases), the bucal mucosa (4 cases), the
maxilla (3 cases), the palate (2 cases) and lastly the retro-
molar triangle (1 case).
The mean cost for Stage III (T3N0M0-T1, T2N1M0) pa-
tients was euro 10,780 (~ US$ 9,500) and their mean hos-
pitalization period was 34.3 days, with a range of 8 to 122
days. The most frequent site for oral cancer development
was the alveolar process (8 cases) and the tongue (7 cas-
es), followed by the retromolar triangle (5 cases), the lips
(4 cases), the bucal mucosa (3 cases), the floor of the
mouth (2 cases) and the palate (2 cases).
Finally, the mean cost for the 13 patients classified as hav-
ing stage IV OSSC was euro 11,950 (~ US$ 10,520) and
their mean hospitalization period was 39 days, with a
range of 9 to 94. Tumors were mainly located on the
tongue and the floor of the mouth (6 cases), followed by
the alveolar process (5 cases), the retromolar triangle (1
case) and the palate (1 case).
Treatment modality per TNM stage of disease exhibited
significant heterogeneity; 90% of stage I OC patients were
treated only by surgery, whereas less than 10% of the pa-
tients in stages III and IV were treated with a single modal-
ity; more than 90% of those with advanced cancer
received multi-modality treatments, e.g. surgery plus radi-
ation therapy, surgery plus radiation therapy plus chemo-
therapy or radical radiation therapy plus chemotherapy.
Regarding the variation of inpatient hospitalization, it
was observed that disease stage was associated with the to-
Figure 2
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firmed by the statistical analysis. Hospitalization did not
differ significantly between stages I and II. However, hos-
pitalization was found to be significantly prolonged in
stage III (p < 0.01) and IV (p < 0.01) as compared to stage
1. In addition, the variation in hospitalization length was
found associated with the mode of treatment, with radia-
tion therapy (p < 0.01) and chemotherapy (p < 0.01) be-
ing predictors of prolonged stay. Surgery was not found to
be significantly associated with prolonged hospitaliza-
tion.
Regarding the cost of treating oral cancer, it was shown
that costs increase as the disease progresses. Costs exhibit-
ed a statistically significant increase with each succeeding
stage. In addition, it was found that radiation therapy (p
< 0.01) and chemotherapy (p < 0.01) were both signifi-
cantly associated with monetary increases, whereas the
Table 1: Patient distribution and hospitalization days, stratified by stage of disease and intraoral site
Stage 1 Stage 2 Stage 3 Stage 4
Location No. of 
patients












Mean Hosp. Days 
(range)
Tongue 5 11 (8–18) 7 20,8 (8–68) 7 15,8 (8–31) 3 29 (14–41)
Lip 3 22 (10–30) 8 18,3 (7–35) 4 25,2 (15–43) 0 0
Floor of Mouth 1 17 11 18,2 (6–46) 2 72 (58–86) 3 33 (30–57)
Alveolar Process 1 10 5 26 (12–72) 8 44 (10–122) 5 49,5 (9–94)
Bucal Mucosa 0 0 4 21,5 (12–31) 3 38,6 (24–56) 0 0
Maxilla 0 0 3 30,6 (23–32) 0 0 0 0
Palate 0 0 2 41,5 (13–70) 2 51,5 (28–85) 1 18
Retromolar Triangle 0 0 1 13 5 32,4 (10–67) 1 28
Table 2: Details of cost calculation per clinical category
Item Basis or details of calculation Cost (in US$)
Hospital & facility charges Includes laboratory expenses, radiographs, CT-
scans, biopsy expenses and medications
143.0 (per day, per patient)
Operating Room costs Calculated according to the hours of OR use and 
consists of:
Up to 1 h : 303.0
i) scrubbed nurses' fee and OR expenses 1–2,5 h: 445.0
ii) anesthesiologist's assistant fee and sedative med-
ications costs.
3 h or more: 570.0
Surgeon's Fees Based on Oral Maxillofacial Surgeons Biopsies (minor): 160.0
Association fees (suggested price list) Medium surg.: 210.0
Major surg.: 392.0
Anesthesiologist's Fees. Based on Society of Anesthesiologists fees Minor cases: 210.0
Major cases: 390.0
Radiation Therapy costs 1) Radical Radiation Therapy for local control Total for 1: 2,195.0
2) Post-op Radiation Therapy: Total for 2: 885.0
Chemotherapy costs Daily total chemotherapy costs (hospitalization 
cost + medication costs)
277.0 (per day, per patient)
Other costs 1) Leibinger or AO Titanium Reconstruction plates 
and screws
1) 580.0 per case
2) MEDPOR or other alloplastic material 2) as needed
3) Intensive Care Unit 3) ICU: 785.0 per dayPage 5 of 8
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a predictor of increased costs.
Discussion
The present study is the first attempt to quantify the direct
monetary costs of OC treatment and rehabilitation, in-
curred to the healthcare system of Greece. Cost predictors
and cost reduction strategies were also identified.
Our analysis presented certain methodological challeng-
es. First, the reported costs are computed estimates of di-
rect monetary costs. The estimation process involved two
distinct parts: a) the gathering of accurate data of per-
formed services within a public teaching hospital, as well
as the identification of expense categories (such as chem-
otherapeutic medication cost), and b) the calculated cost-
ing of the above with current market values, as they occur
in private institutions. Such a two-step process was neces-
sary because the State subsidizes healthcare delivery in
public institutions. Public hospital charges are grossly un-
derestimated and they do not reflect the real cost to the
healthcare system. For example, one day of hospitaliza-
tion is charged at euro 73.0–88.0, including all services
performed. The differential between charge and true cost
to the national healthcare system is absorbed by the State.
However, even our approach may lead to underestimate
of true direct costs, due to inherent difficulties in the ac-
counting system of public hospitals to enlist all resources
consumed. Due to such methodological challenges and
the absence of other available national evidence, it is nec-
essary for other groups to replicate our findings.
A second challenge was the fact that we have calculated
just direct costs. As mentioned above, oral cancer therapy
is associated with multiple indirect costs, such as reduced
productivity during hospitalization and recovery, loss of
income, potential inability to perform previous tasks be-
cause of deformity and functional problems, costs of var-
ious co-morbidities, shortening of life years and reduction
in the quality of life, etc. Thus, the present analysis follows
a cost minimization approach. Total true costs may exceed
the reported direct costs, but their exact calculation is a
subject to a future investigation.
A third challenge was the fact that our data come from the
records of a single institution, and oral cancer treatment
may not be representative for all cases in Greece. Howev-
er, anecdotal evidence from tumor boards of this and oth-
er major hospitals in the vicinity of Athens suggest a
homogeneous approach in the management of OC. The
retrospective review of the records could also bias the re-
sults if record keeping was not homogeneous during the
last 7 years. To minimize such bias, we chose to review
both the individual patient files as well as the official clin-
ic records.
The total direct costs for treating this group of 95 OC
Greek patients in 2002 would be approximately euro
802,300. If we were to extrapolate to the total group of in-
cident cases per year in Greece, then the annual national
cost for the clinical management of oral cancer would be
euro 5,500,000 or approximately 4,830,000 US dollars.
The above figure is a conservative estimate; it probably is
an underestimate of true costs, as it does not include indi-
rect costs.
The average cost of treatment per patient was estimated at
US$ 7,450. Compared to similar treatments elsewhere in
Europe or the United States, the clinical management of
oral cancer in Greece, in absolute terms, seems low. In the
Netherlands, Van Agthoven et al. reported an average cost
of US$ 22,080 (25,096 euros) on the basis of 306 patients
with a primary OC tumor [9]. In the United States, Funk
et al reported an average cost of US$ 32,500 after evaluat-
ing 73 patients with a primary oral cavity tumor [10].
However, relative to the Gross Domestic Product per cap-
ita in Greece, treating oral cancer requires 65% of a per-
son's annual salary (8-month salaries).
The stratified analysis of costs per patient by stage of dis-
ease revealed that treatment cost varied according to the
severity of the disease. It ranged from approximately US$
3,662 for Stage I, to US$ 11,467 for Stage IV cancers. Sim-
ilar variation per stage of laryngeal cancer was noted
among others by Morton et al. in New Zealand [11]; their
reported costs ranged from US$ 11,000 to 27,000.
Regarding the frequency of patients in each stage of dis-
ease, we found that 10% were classified as Stage I, 32% as
Stage II, 44% as Stage III and 13% as Stage IV. Waldfahrer
et al. found 11.3% classified as Stage I, 13.2% as Stage II,
29.1% as Stage III and 46.2% as Stage IV [12]. Quer et al
found 59% of oral cavity cancers as advanced stage [13].
Although there are differences within each cell, the three
studies compare well in the percentage of patients with
advanced disease (Stage III or IV), with 57% in our study,
59% reported by Quer and 75.3% reported by Waldfahrer
et al. A lower percentage of advanced disease is reported
in a study from Memorial Sloan-Kettering, with 29% of
the patients having advanced oral cancer [14]
Regarding the length of hospitalization, the average
length of stay at French hospitals, as reported by Pinsolle
et al., was 29 days with the 90% of the patients staying at
the hospital not more than 20 days [15]. Van Agthoven et
al. reported an average of 31 hospitalized days for oral
cavity cancers [9]. In our study, patients with Stage III were
discharged on average after 34.3 days and those with StagePage 6 of 8
(page number not for citation purposes)
BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/12IV after 39 days. Flynn et al. reported that the average
length of stay for OC patients was 18 days [16]. Ryan et al.
reported that OC patients were hospitalized for 9 to 16
days [17]. Thus, our reported hospitalization period
seems significantly higher than in other institutions
abroad. Speculation of the reasons include inefficiencies
of the Greek healthcare system, such as absence of coordi-
nation between different clinics, absence of organized
multidisciplinary teams or tumor boards, unnecessary
beauraucratic controls, low productivity of some hospital
units and the creation of "bottlenecks".
Cost reduction strategies in Greece must incorporate
methods of reducing the hospitalization. Hospitals that
treat OC must maintain a multidisciplinary and highly
specialized team, that is appropriately supported by radi-
ographic and laboratory infrastructure and by available
surgical wards.
Although reducing hospitalization may lower direct costs,
cost reduction strategies should focus on preventing the
need for chemotherapy and radiation treatment. Howev-
er, the reduction in the utilization of multi-modality ther-
apies is only possible if patients are diagnosed in early
stages. The present analysis clearly demonstrated that ad-
vanced stages of OC are strongly associated with higher
costs, mainly due to the fact that multiple modalities of
treatment cost significantly more than surgery. Thus, iden-
tification of the disease at the earliest possible stage would
increase the percentage of patients that are candidates for
single modality therapy. Along with the direct cost sav-
ings, early treatment also results in increased survival and
quality of life (less indirect costs).
The issue of early detection / early diagnosis and therefore
early treatment of OC has received considerable attention
in the literature worldwide. Numerous studies have ad-
dressed pitfalls in the proper detection of oral cancer [18–
20]. Others documented the benefits of early detection
and population screening programs in the proper man-
agement of OC [21–24]. It has been estimated that nearly
25% of the deaths from cancer might be eliminated by
early detection and intervention. The potential cost-effec-
tiveness of screening programs certainly deserves more in-
vestigation.
Costs should not be the primary consideration when
treating OC. Achieving high patient survival while main-
taining a good quality of remaining life seems the highest
priority. However, as society has only limited resources,
minimizing costs cannot be ignored; available funds,
freed from treatment, could be redirected and allocated to
the prevention of disease rather than treatment. Thus,
more studies are needed to document the role of early de-
tection and early treatment to the reduction of healthcare
costs, and more important, to patient survival.
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